Skip to main content
Equibles

XTLB · Xtl Biopharmaceuticals Ltd

Track XTLB — free

Use XTLB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XTLB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.43 -0.13 (-5.04%) At close · Sep 14
Rebalance outlook locked
Market Cap
$6.29M
Shares
2.46M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.43 Open$2.47 Day$2.40–2.51 Since split$2.06–3.90 Avg vol 30d9K Short int11K · 0.5% float · 1.0d Short vol48% DataMar 2026–Sep 2026

Raw chart and full-history price indicators begin at the captured split on Mar 25, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Mar 25, 2026.

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.5%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Bearish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.1 · elevated Equity put/call 0.67
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −13%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 20%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-67% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.46% of float · ▲ +2.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Squeeze score 41
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 121%
annualized · 1-yr
Max drawdown −47%
past year
ATR 8.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−13% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
20% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-67% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.46% of float · ▲ +2.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its range since split · 2026-03-25
Range low $2 Now $2 · 20% Range high $4
vs 50-day avg -13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
XTLB
Xtl Biopharmaceuticals Ltd
this stock
$6.29M — — — 0.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +14.6% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +2.8% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.87B +17.8% — — 2.0%
CSLLY
Csl Ltd
 $58.97B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
0.3%
Net QoQ
-66.3K sh
Top holder
RHUMBLINE ADVISERS
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Rising
Shares short
11.2K
Days to cover
1.0d
Change
+230 sh
View
Short Volume
Short vol %
48%
As of
Sep 14, 2026
Short Total
View
Fails to Deliver
FTD shares
164
Value
$461
As of
Aug 7, 2026
View
Off-Exchange
Off-exchange %
78.2%
Week of
Aug 10, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 5, 2026
This year
21
View

Performance

Raw-price comparisons begin at the captured split on Mar 25, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
XTLB -2.8% -13.2% — -2.4% —
SPY -1.2% -2.0% +16.1% -0.8% +11.6%
vs SPY -1.6% -11.2% — -1.6% —
Key facts CIK 1023549 CUSIP 98386D406 Visit website